2024-514980-25-00已完成1 期
A clinical study of MK-5661 and placebo in healthy people (MK-5661-006)
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Jonathan Kurz
Scientific
Merck Sharp & Dohme LLC
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A clinical study of MK-5661 in healthy people (MK-5661-007)2024-520229-35-00Merck Sharp & Dohme LLC16
已完成
1 期
A clinical study of MK-6916 in healthy people (MK-6916-002)2024-516899-15-00Merck Sharp & Dohme LLC40
已完成
不适用
Single and Multiple Dose Study of MK-5475 in Healthy ParticipantsPulmonary HypertensionjRCT2031210073MSD K.K.48
已完成
2 期
A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)DyslipidemiaNCT00977288Merck Sharp & Dohme LLC408
进行中（未招募）
1 期
KAND567 Versus Placebo in Subjects Hospitalized with COVID-19. A Phase II, Randomized, 2-Arm Parallel-Group, Double-blind Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics.Acute respiratory distress syndrome (ARDS) in COVID-19 infectionMedDRA version: 21.1Level: PTClassification code 10001052Term: Acute respiratory distress syndromeSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 23.1Level: LLTClassification code 10084401Term: COVID-19 respiratory infectionSystem Organ Class: 100000004862EUCTR2020-002322-85-DKKancera AB40